ASND250117C180000
- 0.00
- 0.000.00%
Ascendis Pharma A/S Newsroom
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $181
Goldman Sachs Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $200
Looking Into Ascendis Pharma's Recent Short Interest
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $220
BioMarin Pharmaceutical Sues Ascendis Pharma for Patent Infringement in Germany
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
Evercore ISI Remains a Buy on Ascendis Pharma (ASND)
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $289
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Ascendis Pharma Initiated at Buy by UBS
Ascendis Pharma Analyst Ratings
UBS Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $196
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $203
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing
Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $220
Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults
Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $194
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $167 to $211